Compare · MBX vs NVO
MBX vs NVO
Side-by-side comparison of MBX Biosciences Inc. (MBX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MBX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $196.77B, about 134.9x MBX ($1.46B).
- NVO has been more active in the news (11 items in the past 4 weeks vs 7 for MBX).
- NVO has more recent analyst coverage (25 ratings vs 12 for MBX).
- Company
- MBX Biosciences Inc.
- Novo Nordisk A/S
- Price
- $30.74-2.47%
- $44.05-3.39%
- Market cap
- $1.46B
- $196.77B
- 1M return
- -
- +4.41%
- 1Y return
- -
- -39.50%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 7
- 11
- Recent ratings
- 12
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MBX
- MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026
- MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City
- SEC Form 144 filed by MBX Biosciences Inc.
- Chief Medical Officer Azoulay Salomon exercised 70,003 shares at a strike of $11.65 and sold $2,685,515 worth of shares (70,003 units at $38.36) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by MBX Biosciences Inc.
- MBX Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing
- SEC Form DEFA14A filed by MBX Biosciences Inc.
- Chief Medical Officer Azoulay Salomon sold $6,824 worth of shares (231 units at $29.54), decreasing direct ownership by 2% to 14,769 units (SEC Form 4) (withholding obligation)
- President & CEO Hawryluk P. Kent sold $17,931 worth of shares (607 units at $29.54), decreasing direct ownership by 0.08% to 727,667 units (SEC Form 4) (for withholding tax)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates